AML at 74: A Favorable Mutation and an Unfavorable Gait Speed Pointing in Different Directions
A single patient with newly diagnosed AML carrying a favorable molecular profile and early frailty markers at once. The disagreement isn't about the biology or the geriatric findings individually — it's about which one should set the pace of treatment.
W.H., a 74-year-old retired civil engineer, still drove himself to a weekly bridge game and walked two miles most mornings until a bout of unexplained fatigue and easy bruising sent him to his primary care physician six weeks ago. A CBC showing a white count of 3.2 with an absolute neutrophil count of 0.4, platelets of 68,000 and 22% blasts on the smear led to a marrow biopsy confirming acute myeloid leukemia. Molecular testing returned an NPM1 mutation with wild-type FLT3 and a normal karyotype — the favorable-risk combination, associated with meaningfully better response to intensive therapy and, in some series, real long-term cure potential well past sixty. An ANC of 0.4 is also its own clock: he is neutropenic now, before anyone treats him, so the deliberation the team is about to have is happening on borrowed time rather than at leisure.
That favorable genotype is only half the picture. A formal geriatric assessment ordered as part of his workup found a gait speed of 0.7 meters per second, under the 0.8 threshold Klepin's work in older adults with AML linked to worse survival independent of disease biology, and a fall in his bathroom eight months ago he'd mentioned only in passing to his primary care physician, not as a leukemia symptom, since it happened before diagnosis. Neither finding is dramatic on its own, and by his account and his family's he remains independent — driving, banking, keeping the bridge game. His creatinine and ejection fraction are both normal, so the organ-function objections that usually decide these conversations are not available to anyone here. What remains is a mismatch between two measurements taken in the same week: a genotype that says treat him like a younger man, and a walking speed that says he may not metabolize seven-plus-three like one. Intensive induction's benefit in NPM1-mutated disease is conditional on surviving induction, and 0.7 m/s is the kind of number that predicts exactly that conditional failing.
Multidisciplinary conference, induction planning
NPM1-mutated, FLT3-wild-type AML is exactly the genotype intensive induction and consolidation are built to cure, and treating him as unfit primarily because he's 74 would waste a molecular profile most patients his age with this disease simply don't have. I'd offer him intensive induction with real long-term intent, not default to the lower-intensity regimen on age alone.
I'm not treating his age as the disqualifying factor — his gait speed and fall history are. Klepin's prospective geriatric-assessment work in older adults receiving intensive AML induction found impaired physical performance predicted worse survival independent of karyotype and age, and both of her markers are present here rather than hypothetical. A favorable genotype doesn't help him if he doesn't survive the regimen built to exploit it.
The comparison isn't 'favorable genotype versus generic age-based caution' — it's favorable genotype versus two specific, reproducible frailty markers that predict exactly the outcome we're trying to avoid.
There's a way to test both positions rather than choose between them today: a time-limited course of venetoclax-azacitidine — the VIALE-A regimen, in the population VIALE-A actually enrolled, patients deemed unsuitable for intensive induction — with formal reassessment of both his leukemia response and his functional status after the first cycle. If he tolerates it well and shows a strong molecular response, that itself is useful information about his actual resilience that the geriatric assessment alone can't fully predict — and if the leukemia isn't clearing adequately at low intensity, that's the moment to revisit intensive induction with clearer eyes about what we're actually risking.
Agreed: start venetoclax-azacitidine now, with a formal joint hematology-geriatrics reassessment scheduled at the end of cycle one covering both leukemia response and functional status.
Not agreed: the hematologist-oncologist's read that this approach risks under-treating a genuinely curable leukemia was not resolved, only deferred — if cycle one shows a strong molecular response and stable function, the case for staying the lower-intensity course strengthens; if it doesn't, intensive induction returns to the table with a clearer picture of what his body can actually tolerate.